Browsing by Author Somaratne, Ransi

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 4 of 4
Issue DateTitleAuthor(s)Citation
2017Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: Secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trialKeech, Anthony (Tony); Ferreira, Jorge; Giugliano, Robert P; Huber, Kurt; Lewis, Basil S.; Murphy, S; Pedersen, T; Pineda, Armando Lira; Sabatine, Marc S.; Sever, Peter; Somaratne, Ransi; Tokgozoglu, S. Lale; NH&MRC Clinical Trials CentreClinical efficacy and safety of evolocumab in high-risk patients receiving a statin: Secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trial, JAMA Cardiology, vol.2, 12, 2017,pp 1385-1391
2017Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular diseaseKeech, Anthony (Tony); Fonarow, Gregg; Giugliano, Robert P; Lindgren, Peter; Pedersen, Terje R; Qian, Yi; Sabatine, Marc S.; Sever, Peter; Somaratne, Ransi; van Hout, Ben; Villa, Guillermo; NH&MRC Clinical Trials CentreCost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease, JAMA Cardiology, vol.2, 10, 2017,pp 1069-1078
2014Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trialsSullivan, David; et al, Various; Giugliano, Robert P; Kim, Jae; Koren, Michael J; Raal, Frederick J; Roth, Eli M; Somaratne, Ransi; Stein, Evan; Wasserman, Scott M; Weiss, Robert; School of Public Health: NH&MRC Clinical Trials CentreEfficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials, European Heart Journal, vol.35, 33, 2014,pp 2249-2259
2015PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialSullivan, David; Bridges, Ian; Burgess, Leslie; Cariou, B; Civeira, Fernando; Dufour, Robert; Gaudet, Daniel; Gouni-Berthold, Ioanna; Hovingh, G Kees; Langslet, Gisle; Olsson, Anders; Raal, Frederick J; Scott, Rob; Scott, Russell; Somaratne, Ransi; Stein, Evan; Turner, Traci; Wasserman, Scott M.; NH&MRC Clinical Trials CentrePCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial, The Lancet, vol.385, 9965, 2015,pp 331-340